Advancing Covalent Ligand and Drug Discovery beyond Cysteine
Chemical Reviews · 23.07.2025 · 125 (14) · 6653-6684
DOI: 10.1021/acs.chemrev.5c00001 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Chemical Reviews, online erschienen am 22.05.2025. Verfasst von Gibae Kim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of Texas at Austin, Austin, Texas 78712, United States. Hauptthemen laut MEDLINE: Cysteine, Drug Discovery, Proteins. Die Arbeit wurde bisher 90-mal zitiert (Crossref) und nennt 393 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NIDA NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Targeting intractable proteins remains a key challenge in drug discovery, as these proteins often lack well-defined binding pockets or possess shallow surfaces not readily addressed by traditional drug design. Covalent chemistry has emerged as a powerful solution for accessing protein sites in difficult to ligand regions. By leveraging activity-based protein profiling (ABPP) and LC-MS/MS technologies, academic groups and industry have identified cysteine-reactive ligands that enable selective targeting of challenging protein sites to modulate previously inaccessible biological pathways. Cysteines within a protein are rare, however, and developing covalent ligands that target additional residues hold great promise for further expanding the ligandable proteome. This review highlights recent advancements in targeting amino acids beyond cysteine binding with an emphasis on tyrosine- and lysine-directed covalent ligands and their applications in chemical biology and therapeutic development. We outline the process of developing covalent ligands using chemical proteomic methodology, highlighting recent successful examples and discuss considerations for future expansion to additional amino acid sites on proteins.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, University of Texas at Austin, Austin, Texas 78712, United States.
ORCID-Profile: Gibae Kim, Ku-Lung Hsu
Förderung
- NIAID NIH HHS
- NIDA NIH HHS
- NIGMS NIH HHS
- National Science Foundation
- Welch Foundation
- Cancer Prevention and Research Institute of Texas
- U.S. Department of Health and Human Services
- Mark Foundation For Cancer Research
Zitieren
APA
Kim, G., Grams, R. J., & Hsu, K. L. (2025). Advancing Covalent Ligand and Drug Discovery beyond Cysteine. Chemical Reviews, 125(14), 6653-6684. https://doi.org/10.1021/acs.chemrev.5c00001
Vancouver
Kim G, Grams RJ, Hsu KL. Advancing Covalent Ligand and Drug Discovery beyond Cysteine. Chemical Reviews. 2025;125(14):6653-6684. doi:10.1021/acs.chemrev.5c00001
BibTeX
@article{Kim2025,
author = {Kim, Gibae and Grams, R Justin and Hsu, Ku-Lung},
title = {Advancing Covalent Ligand and Drug Discovery beyond Cysteine},
journal = {Chemical Reviews},
year = {2025},
volume = {125},
number = {14},
pages = {6653--6684},
doi = {10.1021/acs.chemrev.5c00001}
}
EUVIMED